title: Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group.
abstract: OBJECTIVE
  To determine the risk of ipsilateral breast events in patients with ductal carcinoma in situ (DCIS) treated with local excision without irradiation.
  
  
  METHODS
  Patients with either low- or intermediate-grade DCIS measuring 2.5 cm or smaller, or high-grade DCIS measuring 1 cm or smaller who had microscopic margin widths of 3 mm or wider and no residual calcifications on postoperative mammograms were eligible for a prospective trial conducted from 1997 to 2002 by the Eastern Cooperative Oncology Group and North Central Cancer Treatment Group. Patients entered in 2000 and later could take tamoxifen if they wished. Median age at last surgery for the entire population was 60 years (range, 28 to 88 years), and median tumor sizes in the two strata were 6 mm and 5 mm, respectively.
  
  
  RESULTS
  With a median follow-up of 6.2 years, the 5-year rate of ipsilateral breast events in the 565 eligible patients in the low/intermediate grade stratum was 6.1% (95% CI, 4.1% to 8.2%). With a median follow-up of 6.7 years, this incidence for the 105 eligible patients in the high-grade stratum was 15.3% (95% CI, 8.2% to 22.5%).
  
  
  CONCLUSIONS
  Rigorously evaluated and selected patients with low- to intermediate-grade DCIS with margins 3 mm or wider had an acceptably low rate of ipsilateral breast events at 5 years after excision without irradiation. Patients with high-grade lesions had a much higher rate, suggesting that excision alone is inadequate treatment. Further follow-up is necessary to document long-term results.
authors.affiliation: North Georgia RadiationTherapy/The Hope Center, Cartersville 30121, USA. lhughesmd@aol.com
authors.forename: Lorie L
authors.initials: LL
authors.lastname: Hughes
authors.forename: Molin
authors.initials: M
authors.lastname: Wang
authors.forename: David L
authors.initials: DL
authors.lastname: Page
authors.forename: Robert
authors.initials: R
authors.lastname: Gray
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Solin
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Davidson
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Lowen
authors.forename: James N
authors.initials: JN
authors.lastname: Ingle
authors.forename: Abram
authors.initials: A
authors.lastname: Recht
authors.forename: William C
authors.initials: WC
authors.lastname: Wood
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen